HomeCompareMPCFF vs PFE

MPCFF vs PFE: Dividend Comparison 2026

MPCFF yields 4000.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MPCFF wins by $3743811617672466.50M in total portfolio value
10 years
MPCFF
MPCFF
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
12.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3743811617672466.50M
Annual income
$3,687,468,229,378,192,700,000.00
Full MPCFF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — MPCFF vs PFE

📍 MPCFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMPCFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MPCFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MPCFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MPCFF
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,134,347,994,971,464,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, MPCFF beats the other by $3,134,347,994,971,464,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MPCFF + PFE for your $10,000?

MPCFF: 50%PFE: 50%
100% PFE50/50100% MPCFF
Portfolio after 10yr
$1871905808836233.25M
Annual income
$1,843,734,114,689,096,400,000.00/yr
Blended yield
98.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MPCFF
No analyst data
Altman Z
0.6
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MPCFF buys
0
PFE buys
0
No recent congressional trades found for MPCFF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMPCFFPFE
Forward yield4000.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR12.4%13.2%
Portfolio after 10y$3743811617672466.50M$51.1K
Annual income after 10y$3,687,468,229,378,192,700,000.00$27,210.54
Total dividends collected$3740070324761762.00M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MPCFF vs PFE ($10,000, DRIP)

YearMPCFF PortfolioMPCFF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$460,300$449,600.00$9,161$701.38+$451.1KMPCFF
2$22,232,034$21,739,513.00$8,610$859.79+$22.22MMPCFF
3$1,126,775,718$1,102,987,441.51$8,366$1,081.25+$1126.77MMPCFF
4$59,929,075,693$58,723,425,674.57$8,483$1,405.66+$59929.07MMPCFF
5$3,345,031,836,956$3,280,907,725,965.03$9,084$1,907.24+$3345031.83MMPCFF
6$195,950,017,215,147$192,370,833,149,603.38$10,418$2,732.78+$195950017.20MMPCFF
7$12,047,352,351,791,656$11,837,685,833,371,448.00$13,007$4,193.56+$12047352351.78MMPCFF
8$777,422,635,368,021,600$764,531,968,351,604,600.00$18,010$7,005.87+$777422635368.00MMPCFF
9$52,657,372,237,638,710,000$51,825,530,017,794,930,000.00$28,216$12,979.89+$52657372237638.69MMPCFF
10$3,743,811,617,672,466,500,000$3,687,468,229,378,192,700,000.00$51,081$27,210.54+$3743811617672466.50MMPCFF

MPCFF vs PFE: Complete Analysis 2026

MPCFFStock

Metro Pacific Investments Corporation, an investment holding company, develops infrastructure assets through its investments in water, toll roads, power generation and distribution, healthcare services, and light rail and logistics in the Philippines. It operates through Power, Toll Operations, Water, Rail, and Others segments. The company provides water and sewerage services through a network of pipelines, pumping stations, and mini-boosters in the West Service Area of Metro Manila; and operates a network of 7,748 kilometers of pipelines. It constructs, operates, and maintains the North Luzon Expressway (NLEX), the NLEX- South Luzon Expressway connector road, and the Cebu-Cordova Link Expressway; operates, manages, and maintains the Subic-Clark-Tarlac Expressway; operates and maintains the Manila-Cavite Toll Expressway; designs, finances, constructs, operates, and maintains the 44.6-km Cavite Laguna Expressway. The company also constructs, operates, and maintains electric distribution systems in 36 cities and 75 municipalities serving 7.4 million customers; owns and operates power plants; and operates and manages 18 hospitals and 6 cancer centers. In addition, it operates and maintains the light rail transit line; designs, develops, and markets real estate properties; and provides electromechanical engineering, construction, e-transaction and bills collection, telecommunications, rail-related operations and maintenance, insurance and re-insurance, and consulting and related manpower services; as well as e-business development, power distribution management, energy systems management, harnessing renewable energy, and electric vehicle and charging infrastructure solutions; and electronic toll collection, facilities management, waste management services. Further, the company engages in the rental and leasing of residential properties, trading, and port management activities. The company was founded in 1986 and is headquartered in Pasig, the Philippines.

Full MPCFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MPCFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MPCFF vs SCHDMPCFF vs JEPIMPCFF vs OMPCFF vs KOMPCFF vs MAINMPCFF vs JNJMPCFF vs MRKMPCFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.